COVID19_BMT

A prospective non interventional study to evaluate the role of immune and inflammatory response in recipients of allogeneic haematopoietic stem cell transplantation (SCT) affected by severe COVID19 infection (COVID19_BMT)

Study design/Summary: This is a non interventional, prospective, multicentre study.

Objectives: The study aims to document the clinical and biological characteristics, including immunological profiling, of allogeneic stem cell transplant recipients presenting with severe COVID 19 infection and its impact on survival. This work may provide the scientific basis for targeted therapy with biological agents in this patient group.

Centres:

  • University Hospitals Bristol NHS Foundation Trust
  • The Royal Marsden NHS Foundation Trust
  • University College London Hospitals NHS Foundation Trust
  • Great Ormond Street Hospital NHS Foundation Trust
  • Manchester University NHS Foundation Trust
  • Cardiff and Vale UHB
  • University Hospitals Birmingham NHS Foundation Trust

Target number of patients: 20-60 patients

Patient population: Adult and paediatric patents (any age) who have received allogeneic stem cell transplantation AND proven COVID19 infection as documented by PCR testing of nasal/ throat swab or NPA AND severe COVID 19 infection as defined by need for supplemental oxygen.

Sponsorship/Funding: Great Ormond Street Hospital, NIHR Blood and Transplant Research Unit & University of Birmingham, funded by the IMPACT network

Trial Status: Open to recruitment

Trial Contacts:

covid19bmt@trials.bham.ac.uk

Research.Governance@gosh.nhs.uk

Start date: 04-May-2020

Duration: TBC

If you are a patient and interested in taking part in a clinical trial, please speak with your consultant who will be able to offer you further information and discuss whether it is suitable for you. A referral from your medical team would be required in order to consider you for treatment on a clinical trial.